Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Subscribe To Our Newsletter & Stay Updated
